Author's response to reviews

Title: TGFbeta-mediated suppression of CD248 in non-cancer cells via canonical Smad-dependent signaling pathways is uncoupled in cancer cells

Authors:

Sahana Suresh Babu (sana.suresh@gmail.com)
Yanet Valdez (yvaldez@mail.ubc.ca)
Andrea Xu (wenzhu_andrea_xu@hotmail.com)
Alice O'Byrne (o.byrne@hotmail.com)
Fernando Calvo (fernando.calvo@icr.ac.uk)
Victor Lei (victor.lei@ubc.ca)
Edward M Conway (ed.conway@ubc.ca)

Version: 3
Date: 8 January 2014

Author's response to reviews:

Reviewer 1 (Dr. Iampropoulos)
This reviewer did not ask for any changes.

Reviewer 2 (Teicher)
1. "p 3, lines 15-17: …. and in subsets of carcinomas …..
   We have made this change to the text as recommended.

2. "p 3: CD248 is also expressed in placenta….
   We have added this sentence in the Introduction as recommended.

3. "p 4 or Discussion: MORAb004 is in multiple Phase 1 clinical trials….
   We have included that important information in the Discussion (last paragraph).

4. "p 8, lines 5-7: … as assessed by Western blot….
   We have made this change to the text as recommended.

5. "PMA is not a growth factor or cytokine. It would be better ….
   How was it determined which growth factors and cytokines to test?"
   We have adapted the sentence to more clearly indicate that fact, and also indicated the rationale for why we use the specific growth factors and cytokines.

6. "p 9 and Figure 4 Legend: Mention the concentrations of Amanatin and TGFb ….
   We have now done that.

7. "Figure 5A, 5B and legend. Mention the concentration of SB431542 ….
   We have now done that.
8. "Figure 6A, 6B and legend. Mention the concentration of U0126 and SB202190...."
We have now done that.